


Supplementary Figure 1. Flow cytometry using anti-HER2 mAbs. The cells were treated with H₂Mab-77 (10 μ g/mL), H₂Mab-139 (10 μ g/mL), H₂Mab-193 (10 μ g/mL), H₂Mab-215 (10 μ g/mL), H₂Mab-19 (10 μ g/mL), H₂Mab-181 (10 μ g/mL), H₂Mab-41 (10 μ g/mL), and trastuzumab (10 μ g/mL) against CHO-K1, CHO/HER2, HER2-positive breast cancers (BT-474 and SK-BR-3), a triple-negative breast cancer (MDA-MB-468), and non-transformed normal epithelial cells (HaCaT and MCF 10A). The cells were treated with Alexa Fluor 488-conjugated anti-mouse IgG for mouse anti-HER2 mAbs or FITC-conjugated anti-human IgG for trastuzumab. The black line represents the negative control (blocking buffer).



Supplementary Figure 2. Flow cytometry using anti-HER2 mAbs. The cells were treated with H₂Mab-77 (10 $\mu\text{g}/\text{mL}$), H₂Mab-139 (10 $\mu\text{g}/\text{mL}$), H₂Mab-193 (10 $\mu\text{g}/\text{mL}$), H₂Mab-215 (10 $\mu\text{g}/\text{mL}$), H₂Mab-19 (10 $\mu\text{g}/\text{mL}$), H₂Mab-181 (10 $\mu\text{g}/\text{mL}$), H₂Mab-41 (10 $\mu\text{g}/\text{mL}$), and trastuzumab (10 $\mu\text{g}/\text{mL}$) against immortalized normal epithelial cells, including hTERT TIGKs (gingiva), HBEC3-KT (lung bronchus), hTERT-HME1 (mammary gland), hTCEpi (corneal), hTEC/SVTERT24-B (thymus), RPTEC/TERT1 (kidney proximal tubule), and HCEC-1CT (colon). The cells were treated with Alexa Fluor 488-conjugated anti-mouse IgG for mouse anti-HER2 mAbs or FITC-conjugated anti-human IgG for trastuzumab. The black line represents the negative control (blocking buffer).